Compare LGHL & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LGHL | CRIS |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 862.9K | 976.1K |
| IPO Year | 2020 | 2000 |
| Metric | LGHL | CRIS |
|---|---|---|
| Price | $2.51 | $0.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $42.67 |
| AVG Volume (30 Days) | 81.6K | ★ 502.4K |
| Earning Date | 04-30-2024 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.57 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,898,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 31.50 |
| 52 Week Low | $0.22 | $0.33 |
| 52 Week High | $9.54 | $3,180.00 |
| Indicator | LGHL | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 44.35 | 23.27 |
| Support Level | $0.58 | $0.33 |
| Resistance Level | $5.89 | $5.50 |
| Average True Range (ATR) | 0.36 | 0.07 |
| MACD | -0.06 | 0.52 |
| Stochastic Oscillator | 49.64 | 59.80 |
Lion Group Holding Ltd provides an investor-focused trading platform that offers various products and services. The company's current business lines include total return swap (TRS) trading business, contracts for difference (CFD) trading services, and Over-The-Counter (OTC) stock options trading business. It offers these services through its all-in-one Lion Brokers Pro app and a variety of other apps available on iOS, Android, PC, and Mac platforms. The company's clients are mostly well-educated and affluent Chinese investors residing both inside and outside the PRC (excluding the United States). Its operating segments are: OTC Stock option trading, which generates maximum revenue, CFD trading, TRS trading, and Other. Geographically, the company derives maximum revenue from Hong Kong.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.